Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
86 hedge funds and large institutions have $202M invested in Inozyme Pharma in 2025 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 9 increasing their positions, 29 reducing their positions, and 47 closing their positions.
376% more capital invested
Capital invested by funds: $42.5M → $202M (+$160M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
5.59% more ownership
Funds ownership: 72.73% → 78.32% (+5.6%)
11% less funds holding
Funds holding: 97 → 86 (-11)
23% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 47
69% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$15.7M |
| 2 |
GCL
Glazer Capital LLC
New York
|
+$10.7M |
| 3 |
OBAM
ODDO BHF Asset Management
Paris,
France
|
+$7.92M |
| 4 |
TC
Trium Capital
London,
United Kingdom
|
+$7.86M |
| 5 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$5.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$5.25M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.7M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.14M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.87M |
| 5 |
BlackRock
New York
|
-$2.68M |
INZY Hedge Fund Activity: Q2 2025 in Review
86 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q2 2025, worth a combined $202M — up 376% from $42.5M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of INZY and 36 opened new positions — a net loss of 11 holders — while 29 trimmed existing stakes and 9 added.
The largest buyer was Beryl Capital Management, opening a new position worth an estimated $15.7M. The largest seller was Affinity Asset Advisors, cutting an estimated $5.25M.
- 86 institutional investors held Inozyme Pharma (INZY) as of Q2 2025, down from 97 in Q1 2025.
- Funds reported $202M of Inozyme Pharma stock for Q2 2025, up 376% quarter-over-quarter.
- 36 funds opened new Inozyme Pharma positions in Q2 2025 and 47 closed out, a net change of -11 holders.
- The largest Inozyme Pharma buyer in Q2 2025 was Beryl Capital Management, an estimated $15.7M added.
- The largest Inozyme Pharma seller in Q2 2025 was Affinity Asset Advisors, an estimated $5.25M sold.
Based on aggregated 13F filings for Q2 2025.